Ablative Solutions

Executive Summary

Ablative Solutions is a private medical device company advancing the Peregrine System, a novel catheter-based treatment for hypertension that uses dehydrated alcohol to ablate renal nerves. Unlike radiofrequency or ultrasound-based renal denervation systems, the Peregrine System delivers a precise, low-volume ethanol injection to disrupt sympathetic nerve activity in the renal arteries, potentially offering a more durable and cost-effective solution. Hypertension affects over a billion people worldwide, and despite available pharmacological treatments, many patients remain uncontrolled due to poor adherence or resistance. The Peregrine System addresses this gap by providing a minimally invasive, single-procedure alternative. The company has completed early feasibility studies and is progressing toward pivotal trials in the United States and Europe. If successful, the Peregrine System could compete with established players like Medtronic’s Symplicity Spyral and ReCor’s Paradise system, but with a differentiated mechanism that may simplify the procedure and reduce procedure time. Key risks include the need for robust clinical data demonstrating sustained blood pressure reduction and safety, as well as regulatory approval hurdles. The company is privately held and has not disclosed details on funding or valuation, but its technology represents a promising approach in the interventional hypertension space.

Upcoming Catalysts (preview)

• Q4 2026Pivotal Trial Enrollment Completion70% success
• Q3 2026FDA IDE Approval for Pivotal Trial80% success
• Q2 2027Strategic Partnership or Licensing Deal50% success